Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib

Rheumatology (Oxford). 2015 Oct;54(10):1932-4. doi: 10.1093/rheumatology/kev237. Epub 2015 Jul 2.

Authors

Jan H Schirmer¹, Christoph Thorns², Frank Moosig³, Julia U Holle³

Affiliations

¹ Vasculitis Center, Department of Rheumatology and Clinical Immunology, Klinikum Bad Bramstedt and University Medical Center Schleswig-Holstein, Bad Bramstedt and [email protected].
² Institute for Pathology, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
³ Vasculitis Center, Department of Rheumatology and Clinical Immunology, Klinikum Bad Bramstedt and University Medical Center Schleswig-Holstein, Bad Bramstedt and.

PMID: 26139656
DOI: 10.1093/rheumatology/kev237

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Disease Progression
Dose-Response Relationship, Drug
Erdheim-Chester Disease / drug therapy*
Humans
Indoles / therapeutic use*
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Interleukin-1beta / antagonists & inhibitors*
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Remission Induction
Sulfonamides / therapeutic use*
Treatment Failure
Treatment Outcome
Vemurafenib

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Indoles
Interleukin 1 Receptor Antagonist Protein
Interleukin-1beta
Protein Kinase Inhibitors
Sulfonamides
Vemurafenib
canakinumab